(Q62105019)

English

BMS-354825 or Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Previous Imatinib Mesylate

clinical trial

In more languages

default for all languages

No label defined

No description defined

edit

Statements

instance of

clinical trial

0 references

title

A Randomized Multi-Center Open Label Study of BMS-354825 vs Imatinib Mesylate (Gleevec®) 800 mg/d in Subjects With Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have Disease That is Resistant to Iamtinib at a Dose of 400-600 mg/d (English)

0 references

medical condition

leukemia

0 references

sponsor

Jonsson Comprehensive Cancer Center

0 references

country

United States of America

0 references

main subject

chronic phase chronic myelogenous leukemia